Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy

Immune checkpoint inhibitors (ICIs) have recently revolutionized cancer treatment, providing unprecedented clinical benefits. However, primary or acquired therapy resistance can affect up to two-thirds of patients receiving ICIs, underscoring the urgency to elucidate the mechanisms of treatment resi...

Full description

Bibliographic Details
Main Authors: Yiyi Yan, Anagha Bangalore Kumar, Heidi Finnes, Svetomir N. Markovic, Sean Park, Roxana S. Dronca, Haidong Dong
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-07-01
Series:Frontiers in Immunology
Subjects:
immunotherapy
chemotherapy
targeted therapy
radiotherapy
combination therapy
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2018.01739/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2018.01739/full

Similar Items